Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesidolumab in Geographic Atrophy
NCT01527500Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2012
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of tesidolumab in geographic atrophy (GA) (3 arms), sponsored by Novartis. Primary endpoints: Geographic Atrophy Lesion Growth Measured by Fundus Autofluorescence at Day 505 and Safety and Tolerability of a Single Intravitreal Dose at Day 85. Started Jan 2012; status: completed.
02
Drugs
tesidolumab
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT01527500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527500.